Holding(s) in Company

Jan 18, 2013

Advanced Medical Solutions Group plc
(“AMS” or the “Group”)

RNS Number : 9393V
Advanced Medical Solutions Grp PLC
18 January 2013



1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are

Advanced Medical Solutions Group plc  

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to the
notification obligation:

Aviva plc & its subsidiaries    

4. Full name of shareholder(s)
 (if different from 3.):iv

Registered Holder:


BNY (Nominees) Limited                            107,699*


BNY Norwich Union Nominees Limited  1,249,795*


Chase (GA Group) Nominees Limited      7,078,886*


Chase Nominees Limited                             205,800*  


Vidacos Nominees Limited                            65,686*                                           

            * denotes direct interest  


5. Date of the transaction and date on
which the threshold is crossed or

17 January 2013

6. Date on which issuer notified:

18 January 2013

7. Threshold(s) that is/are crossed or
vi, vii

<3% to 4% Change at Direct Interest Level



8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of

if possible using

Situation previous
to the triggering

Resulting situation after the triggering transaction



of shares

Number of voting

% of  voting rights x


Direct xi

Indirect xii



Ordinary Shares


Below Threshold

Below Threshold



Not Disclosable


Not Disclosable



B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial


Conversion Period

Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.

% of voting



C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financial

Exercise price

Expiration date xvii

Conversion period

Number of voting rights instrument refers to


% of voting rights xix, xx







Total (A+B+C)

Number of voting rights

Percentage of voting rights




9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable:

The voting rights are managed and controlled by Aviva Investors Global Services Limited, with the following chain of controlled undertakings:-


Aviva Investors Global Services Limited:

·      Aviva plc (Parent Company)

·      Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc)

·      Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited)

·      Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)





Proxy Voting:

10. Name of the proxy holder:

See Section 4

11. Number of voting rights proxy holder will cease
to hold:

12. Date on which proxy holder will cease to hold
voting rights:

13. Additional information:

Figures are based on a total number of voting rights of  204,618,339 as per the Company’s Total Voting Rights Announcement of 31 December 2012.


14. Contact name:

     Diane Thirkettle, Aviva plc

15. Contact telephone number:

     01603 687803




Note: Annex should only be submitted to the FSA not the issuer

Annex: Notification of major interests in share

A: Identity of the persons or legal entity subject to the notification obligation

Full name

(including legal form of legal entities)


Contact address

(registered office for legal entities)


Phone number & email


Other useful information

(at least legal representative for legal persons)




B: Identity of the notifier, if applicable

Full name


Contact address


Phone number & email


Other useful information

(e.g. functional relationship with the person or legal entity subject to the notification obligation)


C: Additional information

For notes on how to complete form TR-1 please see the FSA website.


This information is provided by RNS
The company news service from the London Stock Exchange




For further information, please contact:

Advanced Medical Solutions Group plc

Tel: 44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations

Consilium Strategic Communications

Tel: 44 (0) 20 3709 5700

Matthew Neal / Lucy Featherstone

Investec Bank PLC (NOMAD & Broker)

Tel: 44 (0) 20 7597 5970

Gary Clarence / David Anderson

HSBC Bank PLC (Broker)

Tel: 44 (0) 20 7991 8888

Sam McLennan / Joe Weaving / Stephanie Cornish

About Advanced Medical Solutions Group plc

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish tissue adhesives specialist.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 800 employees. For more information, please see admedsol.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.